Enzymatic rationale and preclinical support for a potent protein kinase Cβ inhibitor in cancer therapy
Authors:
- Enrique AlvarezEAEnrique Alvarez
- Laurane G MendelsohnLMLaurane G Mendelsohn
- Gulshan AraGAGulshan Ara
- Krishna MenonKMKrishna Menon
- D.Kirk WaysDWD.Kirk Ways
- 1 July 1999
- journal article
- Published by Elsevier in Advances in Enzyme Regulation
- Vol. 39 (1) , 313-327
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- The Phosphorylated 1169-Tyrosine Containing Region of Flt-1 Kinase (VEGFR-1) Is a Major Binding Site for PLCγBiochemical and Biophysical Research Communications, 1997
- Geometric Resistance and Microvascular Network Architecture of Human Colorectal CarcinomaMicrocirculation, 1997
- Clinical significance of the determination of angiogenic factorsEuropean Journal of Cancer, 1996
- The activity and expression of thymidine phosphorylase in human solid tumoursEuropean Journal of Cancer, 1996
- Influence of an anti‐angiogenic treatment on 9L gliosarcoma: Oxygenation and response to cytotoxic therapyInternational Journal of Cancer, 1995
- Expression of Vascular Endothelial Growt Factor and Its Receptors fit and KDR in Ovarian CarcinomaJNCI: Journal of the National Cancer Institute, 1995
- Potentiation of cytotoxic cancer therapies by TNP‐470 alone and with other anti‐angiogenic agentsInternational Journal of Cancer, 1994
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Regulation of c-jun gene expression in HL-60 leukemia cells by 1-.beta.-D-arabinofuranosylcytosine. Potential involvement of a protein kinase C dependent mechanismBiochemistry, 1991
- Inhibition of radiation-induced apoptosis in vitro by tumor promotersBiochemical and Biophysical Research Communications, 1988